Prostate Cancer

According to the Centers for Disease Control and Prevention, prostate cancer is the most common cancer among men in the U.S., not including non-melanoma skin cancer. It is one of the leading causes of death across male populations. So what should you know about the symptoms, screenings and treatment of prostate cancer? >> Read more trending news Symptoms The Centers for Disease Control and Prevention says that different men could have different symptoms, with some men not showing any signs of having prostate cancer. However, the CDC said that if you see any of the following symptoms you should see a doctor quickly: Difficulty starting urination. Weak urination flow. Frequent urination, especially at night. Pain or burning during urination Blood in the urine Pain in the back, hips or pelvis that doesn't go away. The American Cancer Society also states that weakness or numbness in the legs or feet, or loss of bladder or bowel control could be exp

Introduction Myelodysplastic syndromes (MDS) encompasses a heterogeneous group of myeloid neoplasms characterized by inefficient hematopoiesis, morphologic dysplasia, and variable degrees of cytopenias. 1,2 MDS can be indolent or rapidly progressive, and may transform into secondary acute myeloid leukemia (sAML). 1,2 The annual age-adjusted incidence is approximately 4 per 100,000 persons, increasing markedly with advancing age. 3–5 Despite improvements in treatment and increasingly use of allogeneic bone marrow transplantation (allo-HSCT), the five-year overall survival remains around 30%. 5 Denmark is known worldwide for its many high quality population-based health-care registries. 6 The Danish Myelodysplastic Syndromes Database (DMDSD) was launched in 2010 as a nationwide population-based database, currently covering at least 98% of all Danish MDS patients. 7 It contains detailed clinical data on MDS subtypes, comorbidity, laboratory records, cytogenetic alterations, tre

With more than 9000 participants registered to attend remotely, this year's annual meeting began as ever with its two keynote lectures, the first based on Human Reproduction's most downloaded recent paper and the second on emerging techniques to extend the reproductive function of the ovary. The two keynote presentations which opened this year's annual meeting were each of great topical interest. The first, the Human Reproduction lecture, reaffirmed the likelihood that a delay of up to six months in starting IVF treatment – as occurred at the outset of the COVID-19 pandemic - would not compromise outcome, even in patients over the age of 40 and with low measures of AMH.(1) The results, warned investigator Phillip Romanski of the Weill Cornell Medical College in New York, remain applicable, with the pandemic still virulent in some parts of the world and IVF services ever subject to delay and suspension. The second lecture, on 'expanding the ovary's reproductive lifes

Still, Ford knew that prostate cancer disproportionately affects Black men, so he didn't let up. The second provider he saw gave him a prostate specific antigen (PSA) test, which came back alarmingly high. That doctor sent the results to Ford's PCP, who referred Ford to the oncology department at Northwestern Memorial Hospital. They performed blood work a few times and each time, PSA levels came back higher. An MRI was ordered, which showed complications with the prostate, leading to a biopsy and the discovery that Ford indeed had prostate cancer.

Version 1.2021 of the guidelines lists avelumab (Bavencio) as a category 1 preferred maintenance option for patients with cisplatin-eligible and cisplatin-ineligible locally advanced or metastatic (stage IV) bladder cancer. The inclusion is based on data demonstrating an overall survival (OS) advantage to avelumab maintenance plus best supportive care (BSC) in patients with advanced urothelial cancer that had not progressed on frontline platinum therapy compared with BSC alone in the phase 3 JAVELIN Bladder 100 trial 2 , explained Arlene O. Siefker-Radtke, MD, in a presentation during the 2021 NCCN Virtual Annual Conference. In JAVELIN Bladder 100, the addition of avelumab to BSC as maintenance improved the median OS from 14.3 months to 21.4 months, corresponding to a significant 31% reduction in the risk of death (HR, 0.69; 95% CI, 0.56-0.86; P = .001). "Patients who had progressed prior to a 4-week window of starting maintenance avelumab were not included on this trial, so

Friends actor James Michael Tyler revealed that he was diagnosed with prostate cancer three years ago. On NBC's Today on Monday, the actor shared that he was diagnosed with advanced prostate cancer back in 2018, and that the disease has now progressed to stage IV.  Tyler said his cancer was first detected during a routine physical exam at age 56, when his doctor ordered a prostate-specific antigen (PSA) blood test. The test measures the level of a protein that may be found at higher-than-normal levels in men who have prostate cancer, according to the National Cancer Institute (NCI).  "That came back at an extraordinarily high number," Tyler said. "So I knew immediately when I went online and I saw the results of my blood test and blood work that there was obviously something quite wrong there. Nearly immediately my doctor called me and said, 'Hey, I need you to come in tomorrow because I suspect that you may have quite a serious problem with your prostate

The ocular plaque consists of an assembly of discrete sources. (A) Cross section of a 12 mm brachytherapy applicator with 16 sources; (B) the applicator is surrounded by 1.3 mm thick gold shielding to reduce dose outside of the target. (Courtesy: Phys. Med. Biol. 10.1088/1361-6560/ac02d6) "That may be one of the reasons why people in the medical physics world are interested in getting a conformal brachytherapy treatment for the eye." David Medich, an associate professor of physics at Worcester Polytechnic Institute, was explaining why internal radiation, or brachytherapy, may be preferable for treating ocular melanomas over external-beam radiation therapy: using brachytherapy to deliver radiation to an ocular tumour also protects healthy tissues and critical structures, like the optic nerve and retina, from radiation-induced damage. Work recently reported in Physics in Medicine & Biology introduces a new device for intensity-modulated high-dose-rate brachytherap

This article was originally published here Radiother Oncol. 2021 Jun 22:S0167-8140(21)06608-1. doi: 10.1016/j.radonc.2021.06.025. Online ahead of print. ABSTRACT PURPOSE: The five grade group system has been validated for men treated with radical prostatectomy. However, the prognostic value for men treated with radiation therapy is uncertain, with prior studies utilising old techniques and doses. We aimed to validate the ISUP groupings for men treated with contemporary radiation therapy. METHODS: Men with localised prostate cancer treated with image-guided, dose-escalated (≥78Gy) external beam radiation were identified across four institutions. Primary outcome was time to biochemical failure.Harrell's C index assessed performance of the ISUP system against other grading stratifications. RESULTS: 2205 men were included, withmedian follow-up of 5.6 years. Seven-year actuarial rates of biochemical failure for grade groups 1-5 were 9.3%, 10.4%, 13.2%, 12.4% and 23.4%.On m

Dr. Oliver Sartor, Medical Director, Tulane Cancer Center and trial co-principal investigator/Photo courtesy of Tulane University Novartis has a lot to be excited about going into this year's American Society of Clinical Oncology (ASCO) meeting, and the highlight is the company's targeted radioligand therapy (RLT) platform, 177 Lu-PSMA-617, which has demonstrated considerable promise in PSMA-positive metastatic castration-resistant prostate cancer. Today, the Swiss pharma titan announced the results of its Phase III VISION study where 177Lu-PSMA- 617 plus best standard of care (SOC) met both of its primary endpoints, significantly reducing the risk of death by 38% and reducing the risk of radiographic disease progression or death by 60%. The therapy led to a median improvement in overall survival of four months. Novartis will present the findings at ASCO on June 6. "I think this is the most significant advance that I've been a part of in my 31-year career. T

Neurogenic bladder is a condition that occurs when either nerves or the brain cannot communicate effectively with the muscles in the bladder. When this happens, a person may find it difficult to control urination. Up to 70–84% of people with spinal cord injuries may experience neurogenic bladder at some point in their lives. If a person does not receive treatment for it, they could be at risk of certain infections, such as urinary tract infections (UTIs). This article will look at the types and symptoms of neurogenic bladder, as well as its causes and treatment options. Neurogenic bladder occurs when a person's nerves, spinal cord, or brain have problems sending electrical signals to the bladder. This causes difficulty with urination. There are two broad types of neurogenic bladder: overactive and underactive. An overactive bladder may leak urine, whereas an underactive bladder may struggle to release urine. The causes of neurogenic bladder relate to problem

CONCORD, Calif. , June 25, 2021 /PRNewswire/ -- Golden State Dermatology is pleased to announce Curtis A. Raskin , M.D., Ph.D., F.A.A.D., and his team have joined Golden State Dermatology. Dermatologists interested in joining Golden State Dermatology, are invited to learn more at goldenstatedermatology.com/partnership-opportunities. Golden State Dermatology offers state-of-the-art medical, surgical and cosmetic dermatology, Mohs surgery for skin cancer, pathology, and plastic surgery. The group has rapidly grown over the last few years, adding eight new locations in 2019 and eight more in 2020. This most recent acquisition in Concord will offer medical and surgical dermatology treatments. The clinic is located at 2700 Grant St., Suite 309, Concord, CA , in Downtown Concord . Dr. Raskin devotes his practice to the diagnosis and treatment of patients of all ages and all skin conditions. Dr. Raskin received his medical degree and Ph.D. in molecular biology from State University of

Introduction Cancer, a leading cause of death worldwide, is an important public health concern. In 2020, the estimated new cases of lung cancer in men and women were 116,300 and 112,520, respectively. 1 Although lung cancer accounts for only 12.9% of newly diagnosed cancer cases, it is responsible for 23.5% of all cancer-related deaths; this percentage is higher than those associated with breast, colon, and prostate cancers combined. 2 Despite improvements in medical and surgical therapy, the overall 5-year survival for patients with lung cancer is only 19.4%, mainly due to the advanced stage of disease at diagnosis. Only 16.4% of lung cancer cases are localized and suitable for curative resection at the time of diagnosis. 2 Surgical treatment currently offers the best chance for long-term survival in patients with early-stage lung cancer. Unfortunately, surgical resection is not suitable in some cases owing to existing comorbidities, such as liver cirrhosis. Liver cirrhosis (ie